These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26202377)

  • 1. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
    Yu X; Li Z; Yu J; Chan MT; Wu WK
    Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
    Kjersem JB; Ikdahl T; Lingjaerde OC; Guren T; Tveit KM; Kure EH
    Mol Oncol; 2014 Feb; 8(1):59-67. PubMed ID: 24119443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of genomic markers in colorectal cancer treatment.
    Allen WL; Johnston PG
    J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
    Lyskjær I; Rasmussen MH; Andersen CL
    Epigenomics; 2016 Nov; 8(11):1449-1452. PubMed ID: 27779424
    [No Abstract]   [Full Text] [Related]  

  • 8. Which drug combination for colorectal cancer?
    Doggrell SA
    Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
    Jensen NF; Smith DH; Nygård SB; Rømer MU; Nielsen KV; Brünner N
    Scand J Gastroenterol; 2012 Mar; 47(3):340-55. PubMed ID: 22181013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
    Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.
    Xie T; Huang M; Wang Y; Wang L; Chen C; Chu X
    Cell Physiol Biochem; 2016; 40(1-2):62-76. PubMed ID: 27842308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
    Ho C; Ng K; O'Reilly S; Gill S
    Clin Colorectal Cancer; 2005 Nov; 5(4):279-82. PubMed ID: 16356306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction therapy in patients with metastatic colorectal cancer.
    Venook AP
    Semin Oncol; 2003 Aug; 30(4 Suppl 12):25-9. PubMed ID: 14508724
    [No Abstract]   [Full Text] [Related]  

  • 18. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
    Kopetz S; Morris VK; Parikh N; Overman MJ; Jiang ZQ; Maru D; Elvin P; Gallick G
    BMC Cancer; 2014 Sep; 14():660. PubMed ID: 25208577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.